India’s pharma industry faces slowdown in licensing and technology transfers, says report

The article examines the findings of the 2024 Access to Medicine Index, which reveals a slowdown in voluntary licensing and technology transfers within India's pharmaceutical sector. Known for its role in providing affordable generics, India is experiencing a decline in these vital mechanisms that are essential for improving access to medicines in LMICs. The article notes that this decline in non-exclusive licensing agreements, which allow for the generic production of patented drugs, could lead to restricted access to affordable medications. Additionally, the article emphasises that technology transfers, which enable the generic production of patented drugs, are primarily focused on wealthier countries, leaving regions such as sub-Saharan Africa vulnerable to critical medicine shortages.

The article presents the views of Claudia Martinez, Director of Research at the Access to Medicine Foundation, who is quoted as saying: "Developing inclusive business models for low-income countries, engaging in voluntary licensing and technology transfers, and diversifying clinical trial locations are proven strategies for improving access. Achieving real progress will require companies to reassess and adapt their policies to meet equity goals for access to medicines."